Arrowhead to Present at Jefferies 2015 Healthcare Conference

Home/Newsroom/

Arrowhead to Present at Jefferies...

PASADENA, Calif.–(BUSINESS WIRE)–

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical

company developing targeted RNAi therapeutics, today announced that

Arrowhead’s president and chief executive officer Christopher Anzalone,

Ph.D., will present a corporate overview at the Jefferies 2015

Healthcare Conference on June 3, 2015 at 10:00 a.m. EDT.

Investors may access live and archived versions of the audio webcast of

this presentation on the Events and Presentations page of the Company’s

website at http://ir.arrowheadresearch.com/events.cfm.

About Arrowhead Research Corporation

Arrowhead Research Corporation is a biopharmaceutical company developing

targeted RNAi therapeutics. The company is leveraging its proprietary

Dynamic Polyconjugate delivery platform to develop targeted drugs based

on the RNA interference mechanism that efficiently silences

disease-causing genes. Arrowhead’s pipeline includes ARC-520 for chronic

hepatitis B virus and ARC-AAT for liver disease associated with Alpha-1

antitrypsin deficiency.

For more information please visit http://www.arrowheadresearch.com,

or follow us on Twitter @ArrowRes.

To be added to the Company’s email list and receive news directly,

please visit http://ir.arrowheadresearch.com/alerts.cfm.

Source: Arrowhead Research Corporation

Arrowhead Research Corporation
Vince Anzalone, CFA
626-304-3400
ir@arrowres.com
or
Investor

Relations:
The Trout Group
Todd James
646-378-2926
ir@arrowres.com
or
Media:
Russo

Partners
Matt Middleman, M.D.
212-845-4272
matt.middleman@russopartnersllc.com

Source: Arrowhead Research Corporation

News Provided by Acquire Media